ACE and acute myocardial infarction: In this sense, the HOT [13] study was the only one that demonstrated a 15% reduction in the risk of cardiovascular events (p = 0.03) and a 36% reduction in acute myocardial infarction (AMI) (p = 0.002) in persons from Europe, Asia, and America; participants were treated with felodipine and salicylate, plus an ACE inhibitor and a beta-blocker if necessary, in persons with isolated diastolic hypertension.